{
    "clinical_study": {
        "@rank": "89100", 
        "brief_summary": {
            "textblock": "The purpose of this study is to document quality of life, patient satisfaction, effect on\n      itching, and control of psoriasis vulgaris associated with use of\n      calcipotriene/betamethasone dipropionate (Taclonex\u00ae) topical suspension 0.005% / 0.064% for\n      treatment of plaque psoriasis under real-life conditions."
        }, 
        "brief_title": "An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex\u00ae) Topical Suspension, and Effect on Quality of Life", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis Vulgaris", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed and dated informed consent obtained prior to any study related activities\n\n          2. Aged 18 years or above\n\n          3. Either sex\n\n          4. Any race or ethnicity\n\n          5. Attending a hospital outpatient clinic or the private practice of a board-certified\n             dermatologist, dermatology-certified nurse practitioner or physician assistant\n             trained in dermatology\n\n          6. Clinical diagnosis of psoriasis vulgaris involving scalp and/or body amenable to\n             treatment with a maximum of 100 g of topical medication per week.\n\n          7. Patients who receive a prescription of calcipotriene/betamethasone dipropionate\n             (Taclonex\u00ae) topical suspension 0.005% / 0.064% as per an investigator's clinical\n             judgment and in accordance with the US label, and who have access to the medication\n\n          8. Able to communicate with the investigator, read and understand English, and\n             understand and comply with the requirements of the study\n\n        Exclusion Criteria:\n\n          1. Prior treatment with calcipotriene/betamethasone dipropionate (Taclonex\u00ae) topical\n             suspension, 0.005%/0.064%.\n\n          2. Contraindications or any warnings/precautions according to the US label.\n\n          3. Current participation in any other interventional clinical study.\n\n          4. Females who are pregnant, breast-feeding, or females of child-bearing potential\n             wishing to become pregnant during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients attending a hospital outpatient clinic or the private practice of a\n        board-certified dermatologist, dermatology-certified nurse practitioner or physician\n        assistant trained in dermatology"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982552", 
            "org_study_id": "APPEAL"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Betamethasone-17,21-dipropionate", 
                "Betamethasone", 
                "Betamethasone sodium phosphate", 
                "Calcipotriene"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Plaque psoriasis", 
            "calcipotriene", 
            "betamethasone dipropionate", 
            "topical"
        ], 
        "lastchanged_date": "November 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85032"
                    }, 
                    "name": "Alliance Dermatology and Mohs Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fremont", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94538"
                    }, 
                    "name": "Center for Dermatology Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33756"
                    }, 
                    "name": "Academic Alliance Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33134"
                    }, 
                    "name": "Dermatology Associates and Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Corbin", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40701"
                    }, 
                    "name": "Melissa Knuckles Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warren", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48088"
                    }, 
                    "name": "Grekin Skin Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Henderson", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89074"
                    }, 
                    "name": "Bettencourt Skin Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89128"
                    }, 
                    "name": "Las Vegas Skin and Cancer Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Windsor", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08520"
                    }, 
                    "name": "Psoriasis Treatment Center of Central NJ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10155"
                    }, 
                    "name": "Skin Specialty Dermatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Webster", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77598"
                    }, 
                    "name": "Center for Clinical Studies"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23233"
                    }, 
                    "name": "West End Dermatology"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex\u00ae) Topical Suspension, and Effect on Quality of Life", 
        "overall_official": {
            "affiliation": "Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ", 
            "last_name": "Jerry Bagel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean change from baseline", 
            "measure": "Dermatology Life Quality Index (DLQI)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean percent change from baseline", 
                "measure": "Visual Analogue Scale for itching", 
                "safety_issue": "No", 
                "time_frame": "2 and 8 weeks"
            }, 
            {
                "description": "Percent of subjects with controlled disease", 
                "measure": "Patient Global Assessment (PGA)", 
                "safety_issue": "No", 
                "time_frame": "2 and 8 weeks"
            }, 
            {
                "description": "Mean change from baseline", 
                "measure": "Dermatology Life Quality Index (DLQI)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Treatment Satisfaction Questionnaire for Medication (TSQM)-9", 
                "safety_issue": "No", 
                "time_frame": "2 and 8 weeks"
            }, 
            {
                "description": "Percent of patients that have a 5 point or greater change in total score", 
                "measure": "Dermatology Life Quality Index (DLQI)", 
                "safety_issue": "No", 
                "time_frame": "2 and 8 weeks"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}